Oct 05, 2007 (M2 PRESSWIRE via COMTEX) -- Exploration Investor strives to provide you with outstanding market results. We will be your number one resource for all your small and large cap needs. While working to keep you in touch with market activity, we also will keep you updated on the latest press.
Today, October 5 2007, Genesis Technology Group, Inc (OTCBB:GTEC), has jumped back up over 25% following yesterdays profit taking took place. This has been by far the best week of trading in Genesis history following the announcement that they have entered into a reverse merger with a company that owns and controls Laiyang Jiangbo Pharmaceuticals Co., Ltd.
Based on research performed by a U.S. consulting firm and merchant bank, which inspected the LJPC facilities in Laiyang City last month, revenues have grown by an average of 187% over the previous two years, and net income has risen by an average of 748% over the same period.
Mr. Gary L. Wolfson, Genesis CEO since August 2002, reported: ''Since early 2003, Genesis management has earnestly and methodically sought a merger partner. Under the guidance of Dr. Shaohua Tan in China, we screened numerous candidates, and none could match the strength and potential of Laiyang Jiangbo Pharmaceuticals.
''It is an honor to turn over the future of the merged company to the leadership of Mr. Wubo Cao and his experienced team. Mr. Cao shall serve as the Chairman and Chief Executive Officer. It is our belief that the existing Genesis shareholders will be rewarded for their patience and dedication. In many ways, this merger is the crowning achievement of many years of effort and planning by Genesis management.
Investors seem to believe that Genesis Technology Group, Inc undervalued at its current share price of $0.36, as volume continues to climb driving this stock up. We will continue our due-diligence on this company and if we come across any solid information on this company we will be sure to disseminate anything we can.
In other news, Immureboost (immureboost.com) presented a product at the Therapies for Viral Hepatitis Symposium to Boston Scientists. The Immureboost Company presented poster "Normalization of Elevated Liver Enzymes due to V-1 Immureboost Therapy" at the international symposium Therapies for Viral Hepatitis held in Boston on October 29-31, 2002. The abstract of the presentation is published in UK-based medical journal Antiviral Therapy (2002; Vol 7, L115-L116).
|